Egalet Corp (NASDAQ:EGLT) posted positive top-line data from a Phase III study assessing the safety of Egalet-002, developed utilizing an innovative application of the Guardian™ knowhow. Egalet-002 was largely well-tolerated and the occurrence of adverse events reported was normally consistent with outcomes anticipated following treatment with an ER oxycodone formulation. The details Bob Radie, the […]
EmailWire Instagram
This error message is only visible to WordPress admins
Error: No connected account.
Please go to the Instagram Feed settings page to connect an account.